The FDA authorized Paxlovid for people ages 12 and older who weigh at least 88 pounds. We asked Yale Medicine infectious diseases experts common questions about Paxlovid. The FDA also granted an EUA in December to a pill from Merck called molnupiravir (Lagevrio), but some studies suggest that molnupiravir has only a 30% reduction in the risk for hospitalization and death from COVID-19.Īnd as far as convenience, this medication is considered an improvement over treatments like remdesivir (approved by the FDA in October 2020), which is administered by intravenous (IV) injection. It’s important to note that Paxlovid (the brand name for the drug, which is made up of two generic medications-nirmatrelvir and ritonavir) isn’t the only pill available to treat COVID-19.
It shows clear benefit, and it really can prevent hospitalization and death in people who are at high risk.” “It's really our first efficacious oral antiviral pill for this virus. “I think it is the beginning of a ‘game-changer,’” says Scott Roberts, MD, a Yale Medicine infectious diseases specialist. government while there is a public health emergency) and, perhaps most reassuring, it is expected to work against the Omicron variant.
#Best timing synonym for free#
The drug, developed by Pfizer, has a lot of positives: It had an 89% reduction in the risk of hospitalization and death in the clinical trial that supported the EUA, a number that was high enough to prompt the National Institutes of Health (NIH) to prioritize it over other COVID-19 treatments and it’s cheaper than many other COVID-19 drugs (it’s provided for free by the U.S. So, if you test positive for the coronavirus and you are eligible to take the pills, you can take them at home and lower your risk of going to the hospital.
Paxlovid is an oral antiviral pill that can be taken at home to help keep high-risk patients from getting so sick that they need to be hospitalized. The drug was granted an emergency use authorization (EUA) by the Food and Drug Administration (FDA) in December for anyone ages 12 and older who weighs at least 88 pounds, and is at high risk for severe disease. Paxlovid is the latest COVID-19 treatment that’s been all over the news. Because information about COVID-19 changes rapidly, we encourage you to visit the websites of the Centers for Disease Control & Prevention (CDC), World Health Organization (WHO), and your state and local government for the latest information. Note: Information in this article was accurate at the time of original publication. "Thank you, Chrissy Jones, for your invaluable help. "I would like to thank Chrissy Jones for her invaluable help. Speaking of unnecessary verbiage, why do public speakers (and authors in the prefaces to their books) who want to give thanks to someone, or to a group of people, say, Again, perhaps the extra words make up for your interrupting the person you are questioning. Me: "Yes, I do." I mean for Pete's sake, if they see the watch on my wrist, I obviously have the time, so why don't they ask meĪgain, social amenities and customs seem to require a little tact and indirectness, for whatever reason. If you are asking a smart aleck, s/he might simply say "Yes," and not give you the time, until you ask specifically, "What is the time?" Being a bit of a smart aleck myself, I've done that on more than one occasion, especially when the person asking the question says, "I was wondering if you would be so kind as to give me the time." Nevertheless, if all you need is the time, simply asking a person After all, when asking people a question you are interrupting them and "taking" some of their time, which for all of us is a limited quantity! On the other hand, social amenities are OK as far as they go. I'm with you, generally speaking, in that sometimes we are better off simply asking the question. It is deferential, with its word would, and it flatters the person being asked by implying s/he is kind-and that not giving you the office hours would make him/her unkind! "Would you be so kind as to give me your office hours?"